Haleon Regulatory News (HLN)

Haleon plc: Board and Committee Changes

15 December 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that Alan Stewart will succeed Vindi Banga as Senior Independent Director ("SID"), upon Vindi's appointment as Chair with effect from 1 January 2026.

Alan Stewart joined the Board as a Non-Executive Director and Chair of the Audit & Risk Committee in September 2024. Alan will remain Chair of the Audit & Risk Committee and a member of the Remuneration Committee, Nominations & Governance Committee and Environmental & Social Sustainability Committee following his appointment as Senior Independent Director.

In accordance with the UK Corporate Governance Code 2024, Vindi will step down as a member of the Audit & Risk Committee effective 31 December 2025. Vindi will also step down as a member of the Remuneration Committee effective 31 December 2025 and be appointed Chair of the Nominations & Governance Committee effective 1 January 2026.

Further to the announcement on 10 November 2025, the Company confirms that Vindi Banga's remuneration as Chair will be £757,103 per annum. Further details will be disclosed in the Company's 2025 Annual Report & Accounts.

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R.

Amanda Mellor

Company Secretary

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.